Cabaletta Bio Is A Clinical Stage Biotechnology Company Based In Philadelphiapafocused On Developing Engineered T Cell Therapies For Autoimmune Diseasesthe Company Aims To Transform Treatment Options By Creating Potentially Curative Therapies That Reduce Or Eliminate The Need For Long Term Immunosuppressiontheir Proprietary Cabaletta Approach To B Cell Ablationcabaplatform Includes Innovative Strategies Like The Chimeric Antigen Receptor T Cells For Autoimmunitycartaand The Chimeric Autoantibody Receptor Tcaartcabaletta Bio Is Advancing Several Investigational Therapiesincluding Caba 201Which Targets Conditions Such As Systemic Lupus Erythematosus And Myasthenia Gravisand Two Caart Candidatesdsg3 Caart And Musk Caartaimed At Mucosal Pemphigus Vulgaris And Musk Myasthenia Gravisrespectivelythese Therapies Are Designed For One Time Administration To Provide Durable Responsespotentially Changing The Landscape Of Treatment For Patients With Autoimmune Diseases
